Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Raymond James Trust N.A.

Raymond James Trust N.A. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,064 shares of the biopharmaceutical company’s stock after buying an additional 30 shares during the quarter. Raymond James Trust N.A.’s holdings in Regeneron Pharmaceuticals were worth $1,119,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. International Assets Investment Management LLC grew its position in Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after buying an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA increased its stake in Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after buying an additional 59,769 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Regeneron Pharmaceuticals by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after buying an additional 96,266 shares in the last quarter. Finally, TD Asset Management Inc boosted its position in Regeneron Pharmaceuticals by 30.4% in the 2nd quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock valued at $369,484,000 after buying an additional 82,034 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 7.48% of the stock is owned by insiders.

Analyst Ratings Changes

REGN has been the topic of several recent analyst reports. Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday, October 22nd. Leerink Partners restated a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. Finally, Piper Sandler reduced their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $738.00 on Monday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s 50 day moving average is $945.07 and its two-hundred day moving average is $1,027.53. The firm has a market capitalization of $81.10 billion, a P/E ratio of 18.26, a PEG ratio of 2.87 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52 week low of $735.95 and a 52 week high of $1,211.20.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.